For a comprehensive Group A Streptococcus serological panel, you need five key extracellular protein antigens. Specifically, to manufacture a multi-antigen kit—like the classic Streptozyme test—that reliably detects post-streptococcal sequelae, you must source high-purity recombinant versions of streptolysin O (SLO), hyaluronidase (AHase), streptokinase (ASKase), nicotinamide-adenine dinucleotidase (NADase), and deoxyribonuclease B (DNase B). These five proteins, secreted by GAS during active infection, each provoke a distinct host antibody response that correlates with the complications of acute glomerulonephritis and rheumatic fever.
Manufacturing a panel that truly merits the label “comprehensive” is not about casting a wide, random net. It is about strategically selecting the minimal set of virulence factors—streptolysin O, hyaluronidase, streptokinase, NADase, and DNase B—that collectively cover the immunological signatures of invasive Group A Streptococcus disease. Using recombinant versions of these five extracellular antigens guarantees assay reproducibility and eliminates the cross-reactivity rife in older, culture-derived preparations.
The Five Pillars of a Comprehensive GAS Serological Panel
The core of any serological diagnostic for post-streptococcal disease lies in detecting antibodies the patient has generated against secreted virulence factors. Relying on a single marker, such as anti-streptolysin O alone, misses a significant portion of true infections. A comprehensive panel, therefore, pairs the body's response to each of these five extracellular proteins to create a robust, multi-parametric view.
Streptolysin O: The Oxygen-Labile Benchmark
This is the most established marker. Streptolysin O is a pore-forming cytotoxin that lyses erythrocytes and other host cells, triggering a strong and early antibody response. Measuring anti-streptolysin O (ASO) titers remains the historical gold standard. However, because SLO is extremely susceptible to oxygen inactivation, using a stable recombinant SLO in the assay is critical; native preparations degrade unpredictably, causing severe lot-to-lot drift in your kit’s sensitivity.
Hyaluronidase: The Spreading Factor
Also known as AHase, this enzyme degrades hyaluronic acid in host connective tissue, facilitating bacterial dissemination. Anti-hyaluronidase antibodies appear reliably in the convalescent phase of infection and are particularly valuable for detecting streptococcal pyoderma, where the ASO response is often weak. Incorporating recombinant hyaluronidase enhances the panel’s sensitivity for skin-related infections that can lead to glomerulonephritis.
Streptokinase: The Clot Buster
Streptokinase activates human plasminogen to dissolve fibrin clots, a key tool the bacteria use to escape localized immune containment. Antibodies to streptokinase (ASKase) can provide independent confirmation of recent infection. The inclusion of this antigen becomes especially important when evaluating patients with possible rheumatic fever, as the immune response to streptokinase often parallels disease chronicity in ways a single-marker test would miss.
Nicotinamide-Adenine Dinucleotidase: The Energy Saboteur
Often the most overlooked, NADase (also referred to as the anti-NAD antigen) is a potent enzymatic toxin that depletes cellular energy stores by cleaving NAD+. Anti-NAD antibodies are a proven but underutilized marker. Adding recombinant NADase to your panel fills a detection gap for strains that may not elicit a robust ASO or anti-DNase B response, thereby strengthening overall diagnostic sensitivity without sacrificing specificity.
Deoxyribonuclease B: The Key to the Superantigen Landscape
DNase B is arguably the most critical partner antigen to SLO. It cleaves host DNA, degrading the neutrophil extracellular traps designed to contain the infection. The anti-DNase B response is exceptionally strong after both pharyngeal and skin infections, making it the single best supplement to ASO testing. In the context of acute glomerulonephritis, monitoring anti-DNase B titers is non-negotiable, as many nephritogenic strains provoke this response preferentially.
Understanding the Trade-offs and Manufacturing Pitfalls
While the five-antigen approach creates a superior panel, raw material selection contains hidden risks that directly impact the commercial viability and clinical accuracy of your assay.
The Trap of Native vs. Recombinant Proteins
Historically, manufacturers extracted these antigens from culture supernatants of GAS strains. This produces a mixed, poorly defined preparation containing contaminating proteins that drive unacceptable background noise and cross-reactivity. Recombinant protein expression is now the only viable path for a modern, reproducible diagnostic. It allows you to isolate a single, immunodominant epitope region, eliminating batch-to-batch variation. The lesson is simple: never accept a native preparation when a high-purity recombinant form of SLO, DNase B, or any of the other five is available.
Sensitivity Gaps and Serological Window
No single panel, not even a comprehensive one, detects 100% of infections in real time. The host antibody response is staggered. ASO titers peak first, while anti-DNase B and anti-hyaluronidase may persist longer and are more reliable for diagnosing late-presenting acute glomerulonephritis. If your goal is to manufacture a kit for “early detection,” you might prioritize ASO and streptokinase. For ruling out rheumatic fever or glomerulonephritis weeks after a sore throat, the panel is only effective if it includes the long-lived markers DNase B and hyaluronidase, highlighting why all five are essential for a product marketed as “comprehensive.”
Making the Right Choice for Your Diagnostic Kit
Selecting your raw material portfolio depends entirely on the specific clinical claim you intend to submit with your FDA or CE application. Your antigen investment must follow your intended use case.
- If your primary focus is broad screening for post-streptococcal sequelae: You must source all five—SLO, hyaluronidase, streptokinase, NADase, and DNase B—in recombinant form. Any fewer and you will miss serological positives in patients with skin-origin infections.
- If your primary focus is a budget-conscious initial screen with a reflex protocol: Source recombinant SLO and DNase B as a minimal high-sensitivity pairing. Ensure your supply agreement allows future integration of the remaining three antigens to upgrade to a full panel without changing production lines.
- If your primary focus is emerging market surveillance for rheumatic fever: Prioritize recombinant SLO, streptokinase, and DNase B. These three strike an evidence-backed balance between cost containment and epidemiological sensitivity, but you must position it as a focused, rather than comprehensive, panel.
This is where raw material quality stops being a procurement checkbox and becomes the core of your product’s clinical reputation. Sourcing defined, high-purity recombinant antigens empowers your kit to deliver the definitive answer clinicians need to prevent irreversible cardiac and renal damage.
Summary Table:
| Antigen / Virulence Factor | Clinical & Immunological Role | Key Panel Benefit |
|---|---|---|
| Streptolysin O (SLO) | Cytotoxin that lyses erythrocytes; triggers early antibody response | Established benchmark marker; essential for general infection screening |
| Hyaluronidase (AHase) | Spreading factor that degrades connective tissue hyaluronic acid | Superior sensitivity for skin infections (pyoderma) and late sequelae |
| Streptokinase (ASKase) | Dissolves host fibrin clots to promote tissue invasion | Indicates disease chronicity; aids evaluation of rheumatic fever |
| NADase | Toxin that cleaves host cellular NAD+ energy stores | Fills detection gaps for strains with weak ASO or DNase B responses |
| DNase B | Cleaves host DNA and degrades neutrophil extracellular traps | Key partner to SLO; vital for detecting post-streptococcal glomerulonephritis |
Scale Your GAS Assay Production with CamelBio
Developing high-performance serological kits requires reliable, lot-to-lot consistent raw materials. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Eliminate cross-reactivity and lot-to-lot drift with our high-purity recombinant SLO, DNase B, AHase, ASKase, and NADase antigens tailored for your diagnostic platform.
Contact CamelBio Today to request raw material samples and technical support for your assay development!